Instituto Nacional de Câncer

What Instituto Nacional de Câncer does

Instituto Nacional de Câncer (INCA) is a Brazilian federal autarquia (special administrative entity) attached to the Ministry of Health, headquartered in Rio de Janeiro. Founded in 1941 as the Serviço Nacional de Câncer, INCA operates as Brazil's national reference center for cancer control, delivering prevention, early detection, diagnosis, treatment, rehabilitation, and palliative care across five hospital units in Rio de Janeiro — Hospital do Câncer I, II, III, IV, and the Centro de Transplante de Medula Óssea (CEMO). Services are provided free of charge to the Brazilian population through the Sistema Único de Saúde (SUS), with funding flowing from federal tax revenue and Ministry of Health allocations rather than from commercial payers.

INCA's core operational technology is conventional medical infrastructure: radiotherapy, chemotherapy, surgery, bone marrow transplantation, and diagnostic imaging, delivered through its hospital network. The institution also operates a publishing and knowledge-dissemination arm anchored by the Revista Brasileira de Cancerologia (RBC), a scientific journal launched in 1947 that is currently trilingual (Portuguese, English, Spanish), Qualis CAPES B1-ranked, and indexed in SciELO and Scopus. INCA complements clinical care with a digital engagement layer comprising four mobile applications — Meu INCApp, INCAConecta, Atlas de Mortalidade por Câncer, and Armazém da Saúde — and the Ninho institutional repository for scientific and technical publications. It also runs postgraduate specialization, fellowship, residency, and distance-learning programs in oncology, and coordinates an 11-institution National Cancer Research Consortium.

As a government entity, INCA's revenue model is fully public-sector: managed-services style delivery funded by Ministry of Health allocations, with no commercial pricing, no private customers, and no fundraising activity. The institution has no private equity, venture capital, or individual ownership and operates under transparency, LGPD data-protection, and Programa IntegriSaúde integrity frameworks. Its strategic posture is that of a national coordinator of cancer policy, epidemiology, research, and specialized treatment rather than a commercially scaling enterprise.

Name

Instituto Nacional de Câncer

Legal name

Instituto Nacional de Câncer

Website

https://inca.gov.br

Company type

Private

Founded year

1941

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Instituto Nacional de Câncer (INCA) is Brazil's federal national cancer institute under the Ministry of Health, providing free cancer diagnosis, treatment, research, and education through the SUS across five Rio de Janeiro hospital units and a national research consortium.

Ownership category

akta.pro rank

Product category

Public Cancer Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), General Medical and Surgical Hospitals (622110), Diagnostic Imaging Centers (621512), Offices of Physicians (62111)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

Keywords

• Cancer treatment services
• Oncology research
• Public health administration
• Medical education
• Epidemiological surveillance

Headquarters

HQ city

Rio de Janeiro

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Others

Revenue model

1. Public Healthcare Services: Government-funded healthcare services provided free of charge through Brazil's Sistema Único de Saúde (SUS). INCA operates as a reference center for cancer care, receiving funding from the Ministry of Health to provide diagnosis, treatment, and prevention services to the Brazilian population.

Distribution channels2 records

Marketing channels4 records

Core offering

INCA delivers comprehensive cancer care services through its hospital units in Rio de Janeiro (Hospital do Câncer I, II, III, IV and Centro de Transplante de Medula Óssea), covering diagnosis, surgery, chemotherapy, radiotherapy, and bone marrow transplantation. The institution also coordinates national cancer control policy, conducts epidemiological surveillance, publishes the Revista Brasileira de Cancerologia scientific journal, and runs medical education programs including residencies, specialization courses, and distance learning.

Product overview

Instituto Nacional de Câncer (INCA) is Brazil's national cancer institute operating under the Ministry of Health. It provides a comprehensive portfolio of cancer-related services including treatment across multiple hospital units, research programs, and educational offerings. The institution offers mobile applications (Meu INCApp, INCAConecta, Atlas de Mortalidade por Câncer, Armazém da Saúde) for patient engagement and health information access. INCA publishes the Revista Brasileira de Cancerologia scientific journal and maintains the Ninho institutional repository for research documentation. Patient education is supported through free downloadable cartilhas (guides) covering treatment procedures, nutrition, and social rights. Educational services include postgraduate courses, fellowship programs, and distance learning. The institution focuses on cancer prevention, treatment, research, and public health education through Brazil's unified health system (SUS).

Differentiator

Problem solved

Functional benefit

Brands

• Revista Brasileira de Cancerologia (RBC): Scientific journal in cancerology published by INCA since 1947, currently trilingual (Portuguese, English, Spanish), indexed in SciELO and Scopus, with Qualis B1 ranking (2021-2024).
• Ninho
• Hospital do Câncer I
• Hospital do Câncer II
• Hospital do Câncer III
• Hospital do Câncer IV
• Centro de Transplante de Medula Óssea (CEMO)
• Meu INCApp
• INCAConecta
• Atlas de Mortalidade por Câncer

Products and services

• Meu INCApp Mobile application for patients to access INCA services and information. Available on Google Play and Apple App Store.
• INCAConecta Mobile application connecting patients with INCA healthcare services.
• Atlas de Mortalidade por Câncer Mobile application providing cancer mortality data and statistics visualization.
• Armazém da Saúde Mobile application for health-related content and services.
• Revista Brasileira de Cancerologia (RBC) Scientific journal publishing research on cancer control, indexed in SciELO, Scopus, and Qualis B1. Published trilingually (Portuguese, English, Spanish) since 2023. Available continuously since 1947.
• Ninho Institutional Repository Institutional repository for storing and accessing INCA's scientific and technical publications, theses, and research documents.
• Patient Guidance Materials (Cartilhas) Free downloadable guides for patients covering cancer treatment, nutrition, care procedures, and social rights.
• Educational Courses Postgraduate courses including specialization, fellowship programs, updates, technical training, and distance learning options in oncology.
• Hospital do Câncer I, II, III, IV and Centro de Transplante de Medula Óssea (CEMO) Hospital units providing cancer diagnosis and treatment including surgery, chemotherapy, radiotherapy, and bone marrow transplantation through Brazil's public Sistema Único de Saúde (SUS).

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• National Cancer Research Consortium (11 institutions)coreStrategic or Co-development Partner · 1 January 2026INCA integrates a national consortium for cancer research composed of 11 institutions working collaboratively on cancer research initiatives in Brazil.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/RBCancer1
• YouTubeyoutube.com/user/tvinca
• Facebookfacebook.com/revistabrasileiradecancerologia
• LinkedInlinkedin.com/company/revista-brasileira-de-cancerologia
• Instagraminstagram.com/revbrascancerologia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto Nacional de Câncer